Metabolomic signatures of aggressive prostate cancer

Prostate

Volumn 73, Issue 14, 2013, Pages 1547-1560

  McDunn, Jonathan E ^a   Li, Zhen ^a   Adam, Klaus Peter ^a   Neri, Bruce P ^a   Wolfert, Robert L ^a   Milburn, Michael V ^a   Lotan, Yair ^b   Wheeler, Thomas M ^c  

^a METABOLON INC   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

clinical heterogeneity; diagnosis; metabolomics; prostate cancer

Indexed keywords

CORTICOSTEROID; KYNURENINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; SARCOSINE; SPHINGOMYELIN;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENERGY TRANSFER; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPID METABOLISM; LYMPH NODE; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; ORGAN DONOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEMINAL VESICLE; STRESS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84883189700     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22704     Document Type: Article

References (54)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62 (1): 10-29.
2. Cooperberg MR, Carroll PR, Klotz L,. Active surveillance for prostate cancer: Progress and promise. J Clin Oncol 2011; 29 (27): 3669-3676.
3. Dinan MA, Robinson TJ, Zagar TM, Scales CD Jr, Curtis LH, Reed SD, Lee WR, Schulman KA,. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys 2012; 82 (5): e781-e786.
4. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K,. Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155 (11): 762-771.
5. Gleason DF,. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50 (3): 125-128.
6. Rabets JC, Jones JS, Patel A, Zippe CD,. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004; 172 (1): 94-97.
7. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI,. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50 (3): 498-505.
8. Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ, Xu S, Yan P, Kadoury S, Chua C, Locklin JK, Turkbey B, Shih JH, Gates SP, Buckner C, Bratslavsky G, Linehan WM, Glossop ND, Choyke PL, Wood BJ,. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186 (4): 1281-1285.
9. Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, Giannarini G, Kibel AS, Montironi R, Ploussard G, Roobol MJ, Scattoni V, Jones JS,. Contemporary role of systematic prostate biopsies: Indications, techniques, and implications for patient care. Eur Urol 2012; 63: 214-230.
10. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM,. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457 (7231): 910-914.
11. Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD,. Efforts to resolve the contradictions in early diagnosis of prostate cancer: A comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis 2011; 14 (2): 166-172.
12. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, Lein M, Jung K,. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010; 58 (1): 12-18; discussion 20-21.
13. Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA,. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS ONE 2011; 6 (8): e22486.
14. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G, Jung K,. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2011; 185 (2): 706-711.
15. Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, Vavallo A, Selvaggi FP, Bettocchi C, Battaglia M, Ditonno P,. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 2012; 72 (15): 1611-1621.
16. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA,. Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 2010; 47 (Pt 3): 282.
17. Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P,. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS ONE 2010; 5 (12): e14175.
18. Issaq HJ, Veenstra TD,. Is sarcosine a biomarker for prostate cancer ? J Sep Sci 2011; 34 (24): 3619-3621.
19. Song YH, Shiota M, Kuroiwa K, Naito S, Oda Y,. The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod Pathol 2011; 24 (9): 1272-1280.
20. Chen X, Overcash R, Green T, Hoffman D, Asch AS, Ruiz-Echevarria MJ,. The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels. J Biol Chem 2011; 286 (18): 16091-16100.
21. Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J, Bouchelouche K,. Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol Biol Rep 2011; 38 (7): 4237-4243.
22. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AM,. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 2013; 15 (5): 491-501.
23. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ,. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185 (3): 869-875.
24. Brown MV, McDunn JE, Gunst PR, Smith EM, Milburn MV, Troyer DA, Lawton KA,. Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies. Genome Med 2012; 4 (4): 33.
25. Wheeler TM, Lebovitz RM,. Fresh tissue harvest for research from prostatectomy specimens. Prostate 1994; 25 (5): 274-279.
26. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29 (9): 1228-1242.
27. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E,. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81 (16): 6656-6667.
28. Sha W, da Costa KA, Fischer LM, Milburn MV, Lawton KA, Berger A, Jia W, Zeisel SH,. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J 2010; 24 (8): 2962-2975.
29. Team RC,. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
30. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289-300.
31. Fisher RA, Bennett JH,. Statistical methods, experimental design, and scientific inference. Oxford, England; New York: Oxford University Press; 1990.
32. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-523.
33. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW,. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69 (6): 1095-1101.
34. Albertsen PC, Hanley JA, Fine J,. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293 (17): 2095-2101.
35. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM,. Urine TMPRS S2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3 (94): 94ra72.
36. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA,. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470 (7333): 269-273.
37. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW,. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207 (2): 339-344.
38. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y,. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324 (5924): 261-265.
39. Montrose DC, Zhou XK, Kopelovich L, Yantiss RK, Karoly ED, Subbaramaiah K, Dannenberg AJ,. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res (Phila) 2012; 5: 1358-1367.
40. Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH,. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 2011; 15 (5): 293-303.
41. Trock BJ,. Application of metabolomics to prostate cancer. Urol Oncol 2011; 29 (5): 572-581.
42. Issaq HJ, Fox SD, Chan KC, Veenstra TD,. Global proteomics and metabolomics in cancer biomarker discovery. J Sep Sci 2011; 34 (24): 3484-3492.
43. Dehaven CD, Evans AM, Dai H, Lawton KA,. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform 2010; 2 (1): 9.
44. Eliasson R,. Accurate determination of glucose in human semen. J Reprod Fertil 1965; 9: 325-330.
45. Williams-Ashman HG, Pegg AE, Lockwood DH,. Mechanisms and regulation of polyamine and putrescine biosynthesis in male genital glands and other tissues of mammals. Adv Enzyme Regul 1969; 7: 291-323.
46. Cooper JF, Imfeld H,. The role of citric acid in the physiology of the prostate: A preliminary report. J Urol 1959; 81 (1): 157-164.
47. Kramer G, Steiner G, Fodinger D, Fiebiger E, Rappersberger C, Binder S, Hofbauer J, Marberger M,. High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol 1995; 154 (5): 1636-1641.
48. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR,. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 1999; 155 (1): 235-245.
49. Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS,. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000; 45 (4): 350-354.
50. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ,. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996; 198 (3): 795-805.
51. Hara T, Kosaka N, Kishi H,. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39 (6): 990-995.
52. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G,. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39 (5): 645-649.
53. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D,. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39 (5): 638-644.
54. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D,. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005; 77 (2): 219-229.